Payer
Data from the study revealed that chronic exposure to cortisol disrupts neuronal network activity and damages long-term potentiation, simulating stress-related cognitive decline.
The two companies will develop affordable peptide therapies aimed at extending women’s lifespan.
The funds will be used to expand operations and attract new partners.
The company received an additional equity investment from OrbiMed.
Sanofi will implement BenchSci's Ascend across its global research organization.
An American Hospital Association webinar revealed that healthcare leaders consider AI integral to their revenue cycle management operation.
The company will use the funds to develop new products, expand its operations and acquire other companies.
The funding boosts the Australia-based company's valuation to $465 million and brings its total raise to almost $100 million.
The company will use the funds to develop AI capabilities and move into weight loss, cardiometabolic care, diabetes, thyroid disorders and cardiovascular disease.
The study aims to help people with speech and mobility challenges use the companies' technologies to interact using brain signals, eye gaze or head pose.